Inovio Receives Accelerated Clearance From FDA for Voceryq; Stock Triples After Hours
Inovio said the FDA approved Voceryq on an accelerated basis for recurrent respiratory papillomatosis; shares rose sharply after hours, per Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Dow Jones Newswires, Inovio Pharmaceuticals reported that the U.S. Food and Drug Administration has given accelerated approval to Voceryq, a treatment aimed at lowering how often adults with recurrent respiratory papillomatosis need surgery. The product was earlier called INO-3107. After the bell, the stock more than tripled, to $2.17.
Inovio says the drug can be ordered and shipped in about 60 days, with a full commercial launch planned for the first quarter of 2027.
why it matters
For a single biotech company, the approval is a stock-specific event, but the sharp after-hours move shows how quickly investors reprice regulatory decisions. Follow-through will depend on the launch timing and how the product sells once it reaches the market.
market impact
Inovio shares: approval supports the stock, sharp after-hours gain
- Inovio shares pressure up — FDA approval opens the path to commercial sales of the drug
tags
instruments
sources
- Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours — Dow Jones Newswires, 30 October 2026 at 22:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗